

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	215051.01902	Appln. No.	10/049,502
Applicants	SEBTI		
Filing Date	February 13, 2002	Group:	1636

M. Marich

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MM A	McCormick, F. Nature 363:15-16 (1993)
MM B	Campbell, S.L. et al., Oncogene 17:1395-1413 (1998)
MM C	Zohn, I.M., et al., Oncogene 17:1415-1438 (1998)
MM D	Barbacid, M., Annu. Rev. Biochem., 56:779-827 (1987)
MM E	Bos, J.L., Cancer Res. 49:4682-4689, (1989)
MM F	Olson, M.F., et al., A. Science 269:1270-1272 (1995)
MM G	Khosravi-Far, R. et al., Mol. Cell. Biol. 15:6443-6453 (1995)
MM H	Qiu, R. G., et al., Nature 374:457-459 (1995)
MM I	Mellor, H. et al., J. Biol. Chem. 273:4811-4814 (1998)
MM J	Jahner, D. et al., Mol. Cell. Biol. 11:3682-3690 (1991)
MM K	Fritz, G., et al., J. Biol. Chem. 270:25172-25177 (1995)
MM L	Zhang, F.L., et al., Annu. Rev. Biochem. 65:241-269 (1996)
MM M	Lebowitz, P.F., et al., J. Biol. Chem. 272:15591-15594 (1997)
MM N	Sebti, S.M., et al., Pharmacol. Ther. 74:103-114 (1997)
MM O	Gibbs, J.B., et al., Annu. Rev. Pharmacol. Toxicol. 37:143-166 (1997)
MM P	Cox, A.D., et al., Biochim. Biophys. Acta 1333:F51-F71 (1997)
MM Q	Lebowitz, P.F., et al., Oncogene 17:1439-1445 (1998)

Examiner	M. Marich	Date Considered	8/5/04
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce		



RECEIVED

NOV 06 2002

TECH CENTER 1600/2900

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995: No persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number 10/049,502

Filing Date February 15, 2002

First Named Inventor Said M. Sebti

Group Art Unit 1646 1636

Examiner Name (not yet assigned) M. Maruch

Attorney Docket Number USF-T144X

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R1	CHEN, Z. et al., Farnesylated and Geranylgeranylated RhoB Suppress the Transformation of PANC-1 Human Pancreatic Cancer Cells; Proceedings of the 91 st Annual Meeting of the American Association for Cancer Research, Volume 14, page 220, abstract no. 1402.	
mm	R2	DU, W. et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB, Molecular and Cellular Biology, Volume 19, number 3, March 1999, pages 1831-1840.g	(
mm	R3	CHEN, Z. et al., Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice, Journal of Biological Chemistry, Volume 275, number 24, June 16, 2000, pages 17974-17978.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
Signature

M. Maruch

Date
Considered

8/5/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.